160 related articles for article (PubMed ID: 8943953)
1. Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes.
Belardinelli L; Shryock JC; Ruble J; Monopoli A; Dionisotti S; Ongini E; Dennis DM; Baker SP
Circ Res; 1996 Dec; 79(6):1153-60. PubMed ID: 8943953
[TBL] [Abstract][Full Text] [Related]
2. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
Zocchi C; Ongini E; Ferrara S; Baraldi PG; Dionisotti S
Br J Pharmacol; 1996 Apr; 117(7):1381-6. PubMed ID: 8730729
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
4. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.
Cunha RA; Johansson B; Constantino MD; Sebastião AM; Fredholm BB
Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):261-71. PubMed ID: 8692280
[TBL] [Abstract][Full Text] [Related]
5. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
Jarvis MF; Schulz R; Hutchison AJ; Do UH; Sills MA; Williams M
J Pharmacol Exp Ther; 1989 Dec; 251(3):888-93. PubMed ID: 2600819
[TBL] [Abstract][Full Text] [Related]
6. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
Dionisotti S; Ferrara S; Molta C; Zocchi C; Ongini E
J Pharmacol Exp Ther; 1996 Sep; 278(3):1209-14. PubMed ID: 8819504
[TBL] [Abstract][Full Text] [Related]
7. G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.
Cunha RA; Constantino MD; Ribeiro JA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):295-302. PubMed ID: 10344528
[TBL] [Abstract][Full Text] [Related]
8. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.
Varani K; Gessi S; Dionisotti S; Ongini E; Borea PA
Br J Pharmacol; 1998 Apr; 123(8):1723-31. PubMed ID: 9605581
[TBL] [Abstract][Full Text] [Related]
9. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.
Varani K; Gessi S; Dalpiaz A; Ongini E; Borea PA
Br J Pharmacol; 1997 Sep; 122(2):386-92. PubMed ID: 9313951
[TBL] [Abstract][Full Text] [Related]
10. A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase.
Hide I; Padgett WL; Jacobson KA; Daly JW
Mol Pharmacol; 1992 Feb; 41(2):352-9. PubMed ID: 1311411
[TBL] [Abstract][Full Text] [Related]
11. Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors.
Müller CE; Maurinsh J; Sauer R
Eur J Pharm Sci; 2000; 10(4):259-65. PubMed ID: 10838015
[TBL] [Abstract][Full Text] [Related]
12. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a low affinity binding site for N6-substituted adenosine derivatives in rat testis membranes.
Mazzoni MR; Buffoni RS; Giusti L; Lucacchini A
J Recept Signal Transduct Res; 1995; 15(7-8):905-29. PubMed ID: 8673723
[TBL] [Abstract][Full Text] [Related]
14. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.
Ji XD; Jacobson KA
Drug Des Discov; 1999 Nov; 16(3):217-26. PubMed ID: 10624567
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.
Merighi S; Varani K; Gessi S; Cattabriga E; Iannotta V; Ulouglu C; Leung E; Borea PA
Br J Pharmacol; 2001 Nov; 134(6):1215-26. PubMed ID: 11704641
[TBL] [Abstract][Full Text] [Related]
16. A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex.
Alexander SP; Curtis AR; Kendall DA; Hill SJ
Br J Pharmacol; 1994 Dec; 113(4):1501-7. PubMed ID: 7889308
[TBL] [Abstract][Full Text] [Related]
17. [3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies.
Fredholm BB; Lindström K; Dionisotti S; Ongini E
J Neurochem; 1998 Mar; 70(3):1210-6. PubMed ID: 9489743
[TBL] [Abstract][Full Text] [Related]
18. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
Kull B; Arslan G; Nilsson C; Owman C; Lorenzen A; Schwabe U; Fredholm BB
Biochem Pharmacol; 1999 Jan; 57(1):65-75. PubMed ID: 9920286
[TBL] [Abstract][Full Text] [Related]
19. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists.
Maemoto T; Finlayson K; Olverman HJ; Akahane A; Horton RW; Butcher SP
Br J Pharmacol; 1997 Nov; 122(6):1202-8. PubMed ID: 9401787
[TBL] [Abstract][Full Text] [Related]
20. Effects of adenosine analogs on inositol 1,4,5-trisphosphate production in porcine coronary artery.
Abebe W; Mustafa SJ
Vascul Pharmacol; 2002 Jul; 39(1-2):89-95. PubMed ID: 12616996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
